Press release
Thursday May 1, 2025
The American Department of Health and Social Services (HHS) and the National Institutes for Health (NIH) have today announced the development of the universal new generation, general standard vaccination platform, using a fully beta-propopopopone (BPL) virus platform.
This initiative represents a decisive change towards transparency, efficiency and complete preparation, funding the internal development of NIHs of influenza vaccines and universal coronavirus, including BPL-1357 and BPL-24910 candidates. These vaccines aim to provide wide spectrum protection against multiple strains of viruses subject to pandemic such as H5N1 avian flu and coronavirus, including SARS-COV-2, SARS-COV-1 and MERS-COV.
“Our commitment is clear: each innovation in the development of vaccines must be based on the science and transparency of gold standards, and subject to the highest standards of security and efficiency tests,” said HHS secretary, Robert F. Kennedy, Jr.
The program realates Barda’s operations with its statutory mission under the Public Health Services Act – to prepare for all the viral threats of the flu, not only those which are currently circulating.
“Generation Gold Standard is a paradigm shift,” said NIH director, Dr. Jay Bhattacharya. “It extends the protection of vaccines beyond the limits specific to the strain and is preparing for the viral threats of the flu – not only that of today, but also of tomorrow – using the technology of traditional vaccines brought to the 21stst century.”
Generation Gold Standard, developed exclusively by the National Institute of Allergies and Infectious Diseases of NIH (Niaid):
- Recalibre The American pandemic preparation. Unlike traditional vaccines that target specific strains, whole virus vaccines inactivated by BPL preserve the structural integrity of the virus while eliminating infecture. This approach induces robust and t immune responses of T cells and offers sustainable protection in various viral families. In addition, the intranasal formulation of BPL-1357 is currently in the IB and II / III phase tests and is designed to block the transmission of viruses-an innovation absent from the current flu and COVID-19 vaccines.
- Embodies effective, transparent and government -led research. The BPL platform is entirely belonging to the government and developed by NIH. This approach ensures radical transparency, public responsibility and freedom of conflicts of commercial interests.
- Mark the future of the development of vaccines. In addition to the flu and coronavirus, the BPL platform is adaptable for future use against the syncytial respiratory virus (RSV), metapneumovirus and parainfluenza. It also offers the unprecedented ability to protect against avian flu without inducing an antigen drift – a major step in the prevention of proactive pandemic.
Clinical trials for universal flu vaccines should start in 2026, with the approval of the Food and Drug Administration (FDA) targeted for 2029. The intranasal BPL-1357 FLUX vaccine, currently in advanced trials, is also on the right track for the FDA exam by 2029.
On the National Institutes of Health (NIH):
The NIH, the country’s medical research agency, includes 27 institutes and centers and is a component of the American department of health and social services. NIH is the main federal agency that leads and supports basic, clinical and translational medical research, and studies the causes, treatments and remedies for common and rare diseases. For more information on the NIH and its programs, visit www.nih.gov.
NIH … Transforming discovery into health®
